Floatz logo

m3814

Metastatic Malignant Neoplasm in the Bone

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Metastatic Malignant Neoplasm in the Bone cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 1/2B
Pembrolizumab
Mayo Clinic
Phase 1/2B
Nivolumab
National Cancer Institute (NCI)
Phase 3B
Epirubicin
Mayo Clinic
Phase 1/2B

View all 26 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →